Analysts are say that big pharma will now have around 1.7 trillion US to spend on buyouts. So they are saying that 2022 and on will be a big opportunity for them. With this unprecedented amount of money, don't be surprized if after the ph1 trail of CHM1101 (CLTX CAR T) they come in with an offer.
That's assuming the ph1 goes well. Especially when we would be up for unmet needs, plus more.
Most likely being the first of many offers and partnerships.
valuation thoughts, page-105
-
- There are more pages in this discussion • 276 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
